Destiny Pharma PLC Result of AGM (7569A)
03 Junio 2021 - 6:03AM
UK Regulatory
TIDMDEST
RNS Number : 7569A
Destiny Pharma PLC
03 June 2021
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Result of Annual General Meeting
Brighton, United Kingdom - 3(rd) June 2021 - Destiny Pharma plc
(AIM: DEST), a clinical stage innovative biotechnology company
focused on the development of novel medicines that can prevent
life-threatening infections, announces that all resolutions
proposed to shareholders at the Annual General Meeting held earlier
today were duly passed.
The full text of each resolution was included in the notice of
the meeting, which was made available on the Company's website and
posted to shareholders on 4(th) May 2021. The results for the
resolutions will shortly be available on the Investors section of
the Company's website, www.destinypharma.com .
Nick Rodgers, Chairman of Destiny Pharma, commented :
"It has been a transformational last six months for Destiny
Pharma. We recently delivered excellent Phase 2b data from our
XF-73 nasal gel clinical study for the prevention of post-surgical
infections and have now started talking to regulators regarding
possible Phase 3 clinical plans . Also, we expanded our pipeline
through the acquisition of NTCD-M3 to take it through its Phase 3
clinical study. NTCD-M3 has the potential to become the leading
treatment for C. difficile infections, targeting a market that is
forecast to grow to $1.7 billion by 2026. We remain committed to
developing our novel products that prevent infections and look
forward to delivering further progress and another successful
year."
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0) 1273 704 440
pressoffice@destinypharma.com
Optimum Strategic Communications
Mary Clark/ Shabnam Bashir/ Manel Mateus
+44 (0) 203 174 1789
destinypharma@optimumcomms.com
finnCap Ltd (Nominated Advisor & Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0) 20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology
company focused on the development of novel medicines that can
prevent life-threatening infections. Its pipeline has novel
microbiome-based biotherapeutics and XF drug clinical assets
including NTCD-M3, a Phase 3 ready treatment for the prevention of
C. difficile infection (CDI) recurrence which is the leading cause
of hospital acquired infection in the US and also XF-73 nasal gel,
which has recently completed a positive Phase 2b clinical trial
targeting the prevention of post-surgical staphylococcal hospital
infections including MRSA. It is also co-developing SPOR-COV, a
novel, biotherapeutic product for the prevention of COVID-19 and
other viral respiratory infections and has earlier grant funded XF
research projects.
For further information on the company, please visit https://www.destinypharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGUORARAUUNRAR
(END) Dow Jones Newswires
June 03, 2021 07:03 ET (11:03 GMT)
Destiny Pharma (LSE:DEST)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Destiny Pharma (LSE:DEST)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024